Exact Sciences Corp. (EXAS)

Exact Sciences Stock Forecast & Price Target

See the Price Targets and Ratings of:

Analyst Rating Consensus

Strong Buy
11 Buy
2 Hold
0 Sell
Based on 13 analysts giving stock ratings to
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EXAS Stock Price Prediction

Average Price Target

▲(83.16% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $66.23 with a high forecast of $110.00 and a low forecast of $40.00. The average price target represents a 83.16% change from the last price of $36.16.
Highest Price Target$110.00Average Price Target$66.23Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Upside / Downside
Upgrade Banner
Canaccord Genuity
Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS), Zimmer Biomet Holdings (NYSE: ZBH) and SAGE Therapeutics (NASDAQ: SAGE)
Evercore ISI
Evercore on Exact Sciences (EXAS): Aetna policy change is not incremental to Cologuard screening intervalEvercore maintains Outperform on Exact Sciences (NASDAQ: EXAS) and PT $60.00.
Bank of America Securities
Exact Sciences (EXAS) PT Lowered to $70 at BofA SecuritiesBofA Securities analyst Derik de Bruin lowered the price target on Exact Sciences (NASDAQ: EXAS) to $70.00 (from $95.00) while maintaining a Buy rating.
Stifel Nicolaus
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Exact Sciences (NASDAQ: EXAS) and Cochlear Limited (Other OTC: CHEOF)
Exact Sciences (EXAS) Guidance Looks Conservative - OppenheimerOppenheimer analyst Kevin DeGreeter reiterated an Outperform rating and $155.00 price target on Exact Sciences (NASDAQ: EXAS) seeing 2022 revenue guidance as conservative based on the multiple levers to drive expansion in number of Cologuard tests per ordering clinician:1) more rapid-than-expected rebound in wellness visits as COVID concerns subside2) improved access for sales people to clinician offices3) growing contribution of reorder rate
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

EXAS Stock Forecast FAQ

What is EXAS’s average 12-month price target, according to analysts?
Based on analyst ratings, Exact Sciences’s 12-month average price target is $66.23.
    What is EXAS’s upside potential, based on the analysts’ average price target?
    Exact Sciences has 83.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EXAS a Buy, Sell or Hold?
          Exact Sciences has a conensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Exact Sciences’s price target?
            The average price target for Exact Sciences is $66.23. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $110.00 ,the lowest forecast is $40.00. The average price target represents 83.16% Increase from the current price of $36.16.
              What do analysts say about Exact Sciences?
              Exact Sciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis